Use of Cemiplimab, an Immune Checkpoint Inhibitor for Conjunctival Intraepithelial Neoplasia.

Kübra Serbest CeylanoğluAnne EisenbergFrancis Paul WordenVictor Mauris ElnerHakan Demirci

Published in: Cornea (2024)

Although conjunctival squamous cell carcinoma tumors are reported to be highly responsive to ICIs, a similar effect has not been observed in 2 patients with CIN. Further studies are needed to evaluate ICIs in the management of CIN.

Keyphrases

high grade
squamous cell carcinoma
cancer therapy
locally advanced
case control
lymph node metastasis
drug delivery
radiation therapy